{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T21:42:20Z","timestamp":1715982140834},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.blre.2011.05.002","type":"journal-article","created":{"date-parts":[[2011,8,16]],"date-time":"2011-08-16T03:20:15Z","timestamp":1313464815000},"page":"223-228","source":"Crossref","is-referenced-by-count":2,"title":["Stem cell transplantation for indolent lymphoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Koen","family":"van Besien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2011.05.002_bb0005","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.1999.01337.x","article-title":"A history of haemopoietic cell transplantation","volume":"105","author":"Thomas","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2011.05.002_bb0010","article-title":"Three decades of transplantation for chronic myeloid leukemia: what have we learnt?","author":"Pavlu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0015","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V84.4.1050.1050","article-title":"Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma","volume":"84","author":"Ratanatharathorn","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0020","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V77.3.649.649","article-title":"Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation","volume":"77","author":"Jones","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0025","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.1995.13.5.1096","article-title":"Allogeneic bone marrow transplantation for refractory and recurrent low grade lymphoma \u2014 the case for aggressive management","volume":"13","author":"Van Besien","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.05.002_bb0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-9343(97)89488-0","article-title":"Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology","volume":"100","author":"Van Besien","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2011.05.002_bb0035","first-page":"1832","article-title":"Allogeneic bone marrow transplantation for low grade lymphoma","volume":"92","author":"van Besien","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0040","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/sj.bmt.1702191","article-title":"Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia","volume":"25","author":"Toze","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0045","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/sj.bmt.1701556","article-title":"High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin","volume":"23","author":"Stein","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0050","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0055","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bbmt.2010.01.008","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review","volume":"16","author":"Oliansky","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0060","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/asheducation-2009.1.610","article-title":"Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy","author":"van Besien","year":"2009","journal-title":"Hematology. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.blre.2011.05.002_bb0065","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/10428190601059746","article-title":"Follicular lymphoma: a historical overview","volume":"48","author":"van Besien","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.05.002_bb0070","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bbmt.2005.02.006","article-title":"Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens","volume":"11","author":"Cutler","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0075","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0080","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","article-title":"Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia","volume":"111","author":"Sorror","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0085","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2006-05-021907","article-title":"Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)","volume":"109","author":"Estey","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0090","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1365-2141.2007.06862.x","article-title":"Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation","volume":"139","author":"Hardy","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.blre.2011.05.002_bb0095","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood.V116.21.2709.2709","article-title":"Pre-donor evaluation of an HLA matched sibling identifies a novel inherited RUNX1 mutation encoding a missense mutation found outside of the RUNT domain in familial platelet disorder","volume":"116","author":"Garcia","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0100","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","author":"Lee","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0105","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.bbmt.2009.01.012","article-title":"Unrelated donor hematopoietic cell transplantation for non-Hodgkin lymphoma: long-term outcomes","volume":"15","author":"van Besien","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0110","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2009.26.9100","article-title":"T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma","volume":"28","author":"Thomson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.05.002_bb0115","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.bbmt.2008.06.005","article-title":"Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options","volume":"14","author":"Dew","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0120","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.05.002_bb0125","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0130","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.bbmt.2006.05.015","article-title":"Performance status and comorbidity predict transplant related mortality after allogeneic hematopoietic cell transplantation","volume":"12","author":"Artz","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0135","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.23375","article-title":"Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation","volume":"112","author":"Sorror","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2011.05.002_bb0140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bbmt.2007.07.016","article-title":"A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0145","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.bbmt.2008.08.004","article-title":"Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation","volume":"14","author":"Artz","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0150","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1182\/blood-2010-01-263624","article-title":"Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase","volume":"115","author":"Pavlu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0155","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12185-010-0632-7","article-title":"C-reactive protein levels before reduced-intensity conditioning predict outcome after allogeneic stem cell transplantation","volume":"92","author":"Remberger","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2011.05.002_bb0160","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.bbmt.2009.10.036","article-title":"Early elevation of C-reactive protein correlates with severe infection and nonrelapse mortality in children undergoing allogeneic stem cell transplantation","volume":"16","author":"McNeer","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0165","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0170","article-title":"T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed lymphoma. Predictors for survival after transplant relapse","author":"Kenkre","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.05.002_bb0175","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/blood-2009-11-255182","article-title":"Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma","volume":"115","author":"Lambert","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0180","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0185","doi-asserted-by":"crossref","first-page":"2585-258a","DOI":"10.1182\/blood-2008-06-162800","article-title":"Nonmyeloablative conditioning for relapsed follicular lymphoma","volume":"112","author":"van Besien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0190","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3324\/haematol.10924","article-title":"Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)","volume":"92","author":"Vigouroux","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2011.05.002_bb0195","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0200","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1200\/JCO.2008.17.7279","article-title":"Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning","volume":"26","author":"Armand","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.05.002_bb0205","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbmt.2006.03.014","article-title":"Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy","volume":"12","author":"Gopal","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0210","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2009-03-211441","article-title":"TLI and ATG conditioning with low risk of graft-versus-host disease retains anti-tumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors","author":"Kohrt","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0215","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1182\/blood.V114.22.197.197","article-title":"Phase I\u2013II study of clofarabine-melphalan-alemtuzumab (CMA) conditioning for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies: determination of MTD and outcomes","volume":"114","author":"van Besien","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0220","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1182\/blood-2010-02-270538","article-title":"Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study","volume":"116","author":"Bethge","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0225","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1056\/NEJMe1010818","article-title":"The role of allogeneic-cell transplantation in leukemia","volume":"363","author":"Kersey","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.05.002_bb0230","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2007-03-082933","article-title":"Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study","volume":"110","author":"Bhatia","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.05.002_bb0235","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2010.210","article-title":"Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study","volume":"24","author":"Baker","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.05.002_bb0240","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.bbmt.2005.12.034","article-title":"Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation","volume":"12","author":"Bacigalupo","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0245","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbmt.2006.09.004","article-title":"Allogeneic stem cell transplantation with T cell-depleted grafts for lymphoproliferative malignancies","volume":"13","author":"Novitzky","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0250","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2008.07067.x","article-title":"Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma","volume":"141","author":"Ingram","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2011.05.002_bb0255","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3109\/10428190903200790","article-title":"Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence","volume":"50","author":"van Besien","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.05.002_bb0260","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","article-title":"Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0265","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.bmt.1700781","article-title":"Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effects","volume":"19","author":"Van Besien","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2011.05.002_bb0270","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbmt.2007.04.013","article-title":"High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma","volume":"14","author":"Bloor","year":"2008","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X11000373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X11000373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T08:52:58Z","timestamp":1592815978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X11000373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0268960X11000373"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2011.05.002","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}